Literature DB >> 11809057

Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452.

Hendrik Luesch1, Wesley Y Yoshida, Richard E Moore, Valerie J Paul, Susan L Mooberry, Thomas H Corbett.   

Abstract

Symplostatin 3 (1), a new analogue of dolastatin 10 (2), has been isolated from a tumor selective extract of a Hawaiian variety of the marine cyanobacterium Symploca sp. VP452. Compound 1 differs from 2 only in the C-terminal unit; the dolaphenine unit is substituted by a 3-phenyllactic acid residue. Symplostatin 3 (1) possesses IC(50) values for in vitro cytotoxicity toward human tumor cell lines ranging from 3.9 to 10.3 nM. It disrupts microtubules, but at a higher concentration than 2, correlating with the weaker in vitro cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809057     DOI: 10.1021/np010317s

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  14 in total

Review 1.  Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.

Authors:  April L Risinger; Lin Du
Journal:  Nat Prod Rep       Date:  2019-11-25       Impact factor: 13.423

Review 2.  Biological targets and mechanisms of action of natural products from marine cyanobacteria.

Authors:  Lilibeth A Salvador-Reyes; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2015-03       Impact factor: 13.423

3.  Targeted natural products discovery from marine cyanobacteria using combined phylogenetic and mass spectrometric evaluation.

Authors:  Lilibeth A Salvador-Reyes; Niclas Engene; Valerie J Paul; Hendrik Luesch
Journal:  J Nat Prod       Date:  2015-01-30       Impact factor: 4.050

4.  The carmaphycins: new proteasome inhibitors exhibiting an α,β-epoxyketone warhead from a marine cyanobacterium.

Authors:  Alban R Pereira; Andrew J Kale; Andrew T Fenley; Tara Byrum; Hosana M Debonsi; Michael K Gilson; Frederick A Valeriote; Bradley S Moore; William H Gerwick
Journal:  Chembiochem       Date:  2012-03-01       Impact factor: 3.164

Review 5.  Bacterial symbionts in agricultural systems provide a strategic source for antibiotic discovery.

Authors:  Timothy R Ramadhar; Christine Beemelmanns; Cameron R Currie; Jon Clardy
Journal:  J Antibiot (Tokyo)       Date:  2013-08-07       Impact factor: 2.649

6.  Integrating Molecular Networking and Biological Assays To Target the Isolation of a Cytotoxic Cyclic Octapeptide, Samoamide A, from an American Samoan Marine Cyanobacterium.

Authors:  C Benjamin Naman; Ramandeep Rattan; Svetlana E Nikoulina; John Lee; Bailey W Miller; Nathan A Moss; Lorene Armstrong; Paul D Boudreau; Hosana M Debonsi; Frederick A Valeriote; Pieter C Dorrestein; William H Gerwick
Journal:  J Nat Prod       Date:  2017-01-05       Impact factor: 4.050

7.  Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.

Authors:  Samantha M Gromek; James A deMayo; Andrew T Maxwell; Ashley M West; Christopher M Pavlik; Ziyan Zhao; Jin Li; Andrew J Wiemer; Adam Zweifach; Marcy J Balunas
Journal:  Bioorg Med Chem       Date:  2016-08-24       Impact factor: 3.641

8.  Antimalarial peptides from marine cyanobacteria: isolation and structural elucidation of gallinamide A.

Authors:  Roger G Linington; Benjamin R Clark; Erin E Trimble; Alejandro Almanza; Luis-David Ureña; Dennis E Kyle; William H Gerwick
Journal:  J Nat Prod       Date:  2009-01       Impact factor: 4.050

9.  Microtermolides A and B from termite-associated Streptomyces sp. and structural revision of vinylamycin.

Authors:  Gavin Carr; Michael Poulsen; Jonathan L Klassen; Yanpeng Hou; Thomas P Wyche; Tim S Bugni; Cameron R Currie; Jon Clardy
Journal:  Org Lett       Date:  2012-05-16       Impact factor: 6.005

Review 10.  Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis.

Authors:  Margarida Costa; João Costa-Rodrigues; Maria Helena Fernandes; Piedade Barros; Vitor Vasconcelos; Rosário Martins
Journal:  Mar Drugs       Date:  2012-09-28       Impact factor: 6.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.